

1fw

Mail Certificate

I hereby confirm that I, Kevin D., McCarthy, have deposited this correspondence along with other documents with the U.S. Postal Service by first class mail, (postage pre-paid) to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on April 4, 2007.

Kevin D. McCarthy
Kevin D. McCarthy
Date April 4, 2007

Patent 0-06-058/16434/US/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Mechoulam et al.
Serial no.: 10/570,737
I.A. Filed: September 8, 2004
Title: PHARMACEUTICAL COMPOSITIONS CONTAINING
(+)CANNABIDIOL AND DERIVATIVES THEREOF AND SOME
SUCH NOVEL DERIVATIVES
Examiner: N/A
Art Unit: N/A

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

Applicant submits the enclosed information disclosure statement that is being filed prior to the receipt of the first office action. Accordingly, it is applicant's opinion that the examiner at the U.S. Patent and Trademark Office should consider these references in determining the patentability of this application.

If Applicant becomes aware of other relevant references that are not cumulative of the submitted references, Applicant will submit them.

Respectfully submitted

Kevin D. McCarthy
Kevin D. McCarthy

Reg. No. 35,278

Roach, Brown, McCarthy & Gruber, P.C.
1620 Liberty Building - 420 Main Street
Buffalo, New York 14202



PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/570,737		
		Filing Date	September 8, 2004		
		First Named Inventor	Raphael Mechoulam		
		Art Unit	N/A		
		Examiner Name	N/A		
Sheet	1	of	4	Attorney Docket Number	0-06-058/16434/US/03

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	BISOGNO, TIZIANA et al., British Journal of Pharmacology, 134 (4):845-852 (2001) XP002319199	
	2	CASU, M. A. et al. (2003) Eur. J. Pharmacol. 459(1): 97-105	
	3	CHESHER, G. B. et al. (1973) Br. J. Pharmacol. 49(4): 588-94	
	4	COLOMBO, G. et al. (1998) Eur. J. Pharmacol. 344(1): 67-9	
	5	FRIDE, E. (1995) Brain Res. 697, 83	
	6	FRIDE, E. (2002) Endocannabinoids in the central nervous system - an overview. Prostaglandins, Leukotrienes and Essential Fatty Acids	
	7	FRIDE, E. and C. SANUDO-PENA (2002) Cannabinoids and endocannabinoids: behavioral and developmental aspects. In: The Biology of Marijuana, ed. E. Onaivi, Harwood Academic	
		Publishers, Reading	
	8	FRIDE, E. and R. MECOULAM (1993) Eur. J. Pharmacol. 231, 313	
	9	GALIEGUE, S. et al. (1995) Eur. J. Biochem. 232(1): 54-61	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/570,737		
		Filing Date	September 8, 2004		
		First Named Inventor	Raphael Mechoulam		
		Art Unit	N/A		
		Examiner Name	N/A		
Sheet	2	of	4	Attorney Docket Number	0-06-058/16434/US/03

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	GARDNER, A.L. et al. (1988) Trends Pharmacol. Sci. Suppl.: 40-3	
	11	GRIFFIN, G. et al. (1997) Eur. J. Pharmacol. 339, 53	
	12	GURWITZ, D. et al. (1994) Eur. J. Pharmacol. 267, 21	
	13	HAEFELY, W. et al. (1990) Trends Pharmacol. Sci. 11(11): 452-6	
	14	HANUS, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96, 14228	
	15	HERKENHAM, M. (1995) Cannabinoid receptors, London, Academic Press: 145-166	
	16	IZZO, A. et al. (2000) Br. J. Pharmacol. 129(8): 1627-32	
	17	IZZO, A.A. et al. (2001) Br. J. Pharmacol. 132, 1411	
	18	JOHNSON, M.R. and MELVIN, L.S. (1986) The discovery of non-classical cannabinoids analgetics. In: Cannabinoids as therapeutic agents. Ed. R. Mechoulam, CRS Press FL, pp. 121-145	
	19	LANDI, M. et al. (2002) Eur. J. Pharmacol. 450, 77	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/570,737		
		Filing Date	September 8, 2004		
		First Named Inventor	Raphael Mechoulam		
		Art Unit	N/A		
		Examiner Name	N/A		
Sheet	3	of	4	Attorney Docket Number	0-06-058/16434/US/03

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	20	MALFAIT, A.M. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 9561	
	21	MARTIN, B. R. et al. (1991) Pharmacol. Biochem. Behav. 40(3): 471-8	
	22	MECHOULAM, R. et al. (1998) Prog. Med. Chem. 35, 199	
		MECHOULAM, R. CRS Press Fl., pp 121-145	
	23	PARKER, L.A. et al. (2002) Neuroreport 13, 567	
	24	PERTWEE, R.G. (1997) Pharmacol. Ther. 74, 129	
	25	PERTWEE, R.G. (2001) Gut 48(6): 859-67	
	26	PINTO, L. (2002) Prostaglandins Leukot Essent Fatty Acids 66, 333	
	27	ROBSON, P. (2001) Br. J. Psychiatry 178, 107	
	28	TJOLSEN, A. and HOLE (1997) The Pharmacology of Pain, Springer, Heidelberg, pp.1-20]	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/570,737		
		Filing Date	September 8, 2004		
		First Named Inventor	Raphael Mechoulam		
		Art Unit	N/A		
		Examiner Name	N/A		
Sheet	4	of	4	Attorney Docket Number	0-06-058/16434/US/03

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	29	Young, J. M. et al. (1984) J. Invest. Dermatol. 82, 367-71	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U. S. Patent and Trademark Office

Inventor:	Mechoulam et al.
Title:	Pharmaceutical Compositions Containing (+) Cannabidiol and Derivatives Thereof and some such novel derivatives
Serial No.:	10/570,737
Int. Filing Date:	September 8, 2004
Examiner:	N/A
Art Unit:	N/A
Information Disclosure Statement:	(1 page)
1449 Documents:	(4 pages)
References:	(29)
Our Ref. No.:	0-06-058 (16434/US/03)
Postcard:	Stamped, self-addressed